Category: 872046-08-7

On June 21, 2007, Bjoere, Annika; Cladingboel, David; Kajanus, Johan; Olsson, Christina; Ponten, Fritiof; Strandlund, Gert published a patent.Synthetic Route of 872046-08-7 The title of the patent was Preparation of oxabispidines for the treatment of cardiac arrhythmias. And the patent contained the following:

Title compounds [I; R1 = (substituted) alkyl, COER7, CONR8aR5d, SO2R9a; R2, R3 = H, F, alkyl; R4 = alkyl, 6-membered (hetero)aryl, etc.; R5d = H, (substituted) alkyl, aryl, (substituted) heterocyclyl, etc.; R8a = H, (substituted) alkyl, alkoxy, etc.; R9a = (substituted) alkyl; R41-R46 = H, alkyl; Z = NR14aCOA, CONR14bB; R14a, R14b = H, alkyl; A = bond, (substituted) alkylene; B = (substituted) alkylene; E = O, S; with specific exclusions], were prepared Thus, N-(4-cyanobenzyl)-2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)acetamide dihydrochloride (preparation given), PhCH2CH2Br, and K2CO3 were heated together in MeCN at 60° for 66 h to give 76.2% N-(4-cyanobenzyl)-2-[7-(2-phenylethyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]acetamide. The latter showed a D10 value of 7.1 for class III electrophysiol. potency in guinea pigs. The experimental process involved the reaction of Methyl 2-(2,6-difluorophenyl)acetate(cas: 872046-08-7).Synthetic Route of 872046-08-7

The Article related to oxabispidine preparation cardiac arrhythmia treatment, antiarrhythmic oxadiazabicyclononane preparation, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.Synthetic Route of 872046-08-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 10, 2022, Yang, Guoqiang; Wu, Hua; Gallarati, Simone; Corminboeuf, Clemence; Wang, Qian; Zhu, Jieping published an article.COA of Formula: C9H8F2O2 The title of the article was Migrative Carbofluorination of Saturated Amides Enabled by Pd-Based Dyotropic Rearrangement. And the article contained the following:

Herein, a palladium-catalyzed migrative carbofluorination of saturated amides enabled by the activation of both the C(sp3)-H and the Cquaternary-Cσ bonds was reported for the synthesis of functionalized amides. In this transformation, the α-quaternary carbon of Weinreb amides was converted to α-tertiary fluoride with concurrent migration of an aryl or an amido group from the α- to β-carbon. DFT calculations indicate that the dyotropic rearrangement proceeds through an unusual anti-selective [2.1.0] bicyclic transition state. The experimental process involved the reaction of Methyl 2-(2,6-difluorophenyl)acetate(cas: 872046-08-7).COA of Formula: C9H8F2O2

The Article related to functionalized amide preparation, saturated amide dyotropic rearrangement migrative carbofluorination palladium catalyst, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.COA of Formula: C9H8F2O2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 24, 2009, Foulon, Loiec; Goullieux, Laurent; Pouzet,brigitte; Serradeil-Le Gal, Claudine; Valette, Gerard published a patent.Recommanded Product: 872046-08-7 The title of the patent was Preparation of 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives as selective V1a arginine vasopressin receptor ligands and in some cases as V1b ligands as well. And the patent contained the following:

The invention is related to the preparation of 3-aminoalkylindolin-2-one derivatives I [X = C1-5 alkylene optionally substituted at ≥1 C atoms by 1 F or by a C1-3 alkyl; R1 = NR8R9, (un)substituted piperidin-4-yl, piperidin-3-yl; R8, R9 = independently H, alkyl; or NR8R9 = heterocyclyl selected from azetidin-4-yl, pyrrolidin-4-yl, morpholin-4-yl, piperazin-4-yl, etc., the C atoms being optionally substituted by ≥1 F atoms; R2 = halo, Alk, OAlk; Alk = = alkyl optionally substituted by ≥1 F atoms; R3 = OMe; R4, R7 = independently H, halo, OH, Alk, OAlk; R5 = H, CO2Alk, CH2OH, R4; R6 = H, OH, Alk, OAlk, cycloalkyloxy, NHCONH2 and derivatives; or R7 is in the 3-position of the Ph group and together with R6 they represent a CH2CH2CH2 radical] their acid addition salts and their hydrates or solvates, having a strong affinity and high selectivity for human V1a arginine vasopressin receptors and in some cases also a strong affinity for V1b receptors. Thus, a multi-step synthesis from 1-chloro-5-fluoro-2-methoxy-4-nitrobenzene and Me 2-(2-fluorophenyl)acetate was given for indolinone (+)-II·×HCl. In an in vitro assay, II bound selectively to human V1a receptor with IC50 = 2.4 nM compared to human V1b, human V2 vasopressin receptors and human oxytocin receptor (Ic50 = >1000 nM, 450 nM and 390 nM, resp.). The V1a antagonistic activity of II was determined in vitro in a FLIPR test measuring the intracellular calcium in cells expressing the human V1a receptors. The experimental process involved the reaction of Methyl 2-(2,6-difluorophenyl)acetate(cas: 872046-08-7).Recommanded Product: 872046-08-7

The Article related to indolinone aminoalkyl preparation selective v2 vasopressin antagonist, vasopressin v2 receptor ligand aminoalkyldihydrohindolone preparation, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Recommanded Product: 872046-08-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 26, 2015, Marcin, Lawrence R.; Higgins, Mendi A.; Bronson, Joanne J.; Zusi, F. Christopher; Macor, John E.; Ding, Min published a patent.Application In Synthesis of Methyl 2-(2,6-difluorophenyl)acetate The title of the patent was Preparation of triazolopyridine ether derivatives useful in treatment of neurological and psychiatric disorders. And the patent contained the following:

The invention relates to compounds of formula I and their preparation, as modulators of the mGluR2 receptor potentially useful for the treatment of various disorders of the central nervous system including neurol. and psychiatric disorders. Compounds of formula I are claimed, in which R1 is H, CN, halo, (halo)alkyl, etc.; R2 is (halo)alkyl, (cycloalkyl)alkyl, etc.; R3 is Ar1 and OAr1; Ar1 is (un)substituted Ph, pyridinyl, pyrimidinyl, etc.; Y is bond and (un)substituted C3-6 cycloalkyl; Z is bond and (un)substituted C1-3 alkyl; provided that when Y and Z are bonds, R3 is Ar1; or pharmaceutically acceptable salts thereof. Example compound II was prepared by cyclocondensation of 2-hydrazinyl-4-((1-phenylcyclohexyl)methoxy)-3-(trifluoromethyl)pyridine with 2-cyclopropylacetyl chloride to afford 2-cyclopropyl-N’-(4-((1-phenylcyclohexyl)methoxy)-3-(trifluoromethyl)pyridin-2-yl)acetohydrazide, which underwent cyclization with Burgess reagent to yield II. Invention compounds were evaluated for their human mGluR2 inhibitory activity. From the assay, it was determined that II exhibited EC50 value of 1.8 nM. The experimental process involved the reaction of Methyl 2-(2,6-difluorophenyl)acetate(cas: 872046-08-7).Application In Synthesis of Methyl 2-(2,6-difluorophenyl)acetate

The Article related to triazolopyridine ether preparation treatment cns neurol psychiatric disorder, Heterocyclic Compounds (More Than One Hetero Atom): Other 6-Membered Rings, Three Or More Hetero Atoms and other aspects.Application In Synthesis of Methyl 2-(2,6-difluorophenyl)acetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 3, 2014, Zeng, Qingping; Faris, Mary; Mollard, Alexis; Warner, Steven L.; Flynn, Gary A. published a patent.SDS of cas: 872046-08-7 The title of the patent was Preparation of heteroarylaminonaphthyridinone derivatives for use as multiple kinase pathway inhibitors. And the patent contained the following:

Title compounds I [R1 = (un)substituted azaheteroaryl; R2 = H, (un)substituted alkyl, cycloalkyl, heterocyclyl, etc.; R3 = H, alkyl, cycloalkyl, (un)substituted alkenyl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as multiple kinase pathway inhibitors. Thus, e.g., II was prepared by a multistep procedure (preparation given). Select I were evaluated in DoHH2 cell cycle proliferation assays, e.g., II demonstrated an EC50 value of <1 μM. The experimental process involved the reaction of Methyl 2-(2,6-difluorophenyl)acetate(cas: 872046-08-7).SDS of cas: 872046-08-7

The Article related to naphthyridinone heteroarylamino preparation multiple kinase pathway inhibitor, Heterocyclic Compounds (One Hetero Atom): Other Areno- and Diarenopyridines (Acridines, Quinolizines, etc.) and other aspects.SDS of cas: 872046-08-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On February 15, 2016, Lavecchia, Martin J.; Puig de la Bellacasa, Raimon; Borrell, Jose I.; Cavasotto, Claudio N. published an article.Formula: C9H8F2O2 The title of the article was Investigating molecular dynamics-guided lead optimization of EGFR inhibitors. And the article contained the following:

The epidermal growth factor receptor (EGFR) is part of an extended family of proteins that together control aspects of cell growth and development, and thus a validated target for drug discovery. The authors explore the suitability of a mol. dynamics-based end-point binding free energy protocol to estimate the relative affinities of a virtual combinatorial library designed around the EGFR model inhibitor 6{1} as a tool to guide chem. synthesis toward the most promising compounds To investigate the validity of this approach, selected analogs including some with better and worse predicted affinities relative to 6{1} were synthesized, and their biol. activity determined To understand the binding determinants of the different analogs, hydrogen bonding and van der Waals contributions, and water mol. bridging in the EGFR-analog complexes were analyzed. The exptl. validation was in good qual. agreement with the authors’ theor. calculations, while also a 6-dibromophenyl-substituted compound with enhanced inhibitory effect on EGFR compared to the reference ligand was obtained. The experimental process involved the reaction of Methyl 2-(2,6-difluorophenyl)acetate(cas: 872046-08-7).Formula: C9H8F2O2

The Article related to pyridopyrimidine egfr inhibitor preparation mol dynamics structure activity binding, egfr, hit-to-lead optimization, ligand binding free energy calculation, mm/gbsa, molecular docking, molecular dynamics, pyrido[2,3-d]pyrimidine, small-molecule inhibitor and other aspects.Formula: C9H8F2O2

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics